BioMarin director granted 7,490 RSUs

BioMarin Pharmaceutical director Mark J. Enyedy received a stock-based compensation award.

Rhea-AI Filing Summary

BioMarin Pharmaceutical director Mark J. Enyedy received a stock-based compensation award. On June 2, 2026, he acquired 7,490 shares of common stock through a grant of restricted stock units, with no cash price per share. After this award, he directly holds 21,040 common shares.

Insider Trade Summary

Grant/Award: 7,490 shares

Grant/Award 1 txn

Insider Enyedy Mark J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,490	$0.00	$0.00

Holdings After Transaction: Common Stock — 21,040 shares (Direct)

Footnotes (1)

1. F1. Restricted stock units granted on June 2, 2026. Price not applicable.

Key Figures

RSU grant size: 7,490 shares Grant price: $0.0000 per share Post-transaction holdings: 21,040 shares

3 metrics

RSU grant size 7,490 shares Restricted stock units granted on June 2, 2026

Grant price $0.0000 per share Price not applicable for RSU grant

Post-transaction holdings 21,040 shares Common stock directly held after the grant

Key Terms

Restricted stock units, Grant, award, or other acquisition, Common Stock

3 terms

Restricted stock units financial

"Restricted stock units granted on June 2, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioMarin (BMRN) director Mark Enyedy report in this Form 4 filing?

Mark J. Enyedy reported receiving a grant of 7,490 restricted stock units of BioMarin common stock on June 2, 2026. This is a stock-based compensation award rather than an open-market purchase or sale of shares.

How many BioMarin (BMRN) shares does Mark Enyedy hold after this RSU grant?

Following the June 2, 2026 restricted stock unit grant, Mark J. Enyedy directly holds 21,040 shares of BioMarin common stock. This total reflects his position immediately after the reported compensation-related acquisition.

Was there a purchase price for Mark Enyedy’s BioMarin (BMRN) stock award?

No cash purchase price applied to this award. The Form 4 and footnote state that the 7,490 restricted stock units granted on June 2, 2026 have price not applicable, consistent with stock-based compensation rather than a market transaction.

What transaction code is used for Mark Enyedy’s BioMarin (BMRN) Form 4 award?

The transaction is coded “A” for grant, award, or other acquisition. The filing describes it as a grant of restricted stock units, indicating a compensation-related acquisition instead of an open-market buy or sell of BioMarin shares.

Is Mark Enyedy’s BioMarin (BMRN) Form 4 transaction a buy or sell signal?

The transaction is an acquisition via restricted stock units, not an open-market buy or sell. It reflects routine equity compensation for a director, rather than a discretionary decision to purchase or dispose of BioMarin shares in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 06:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Enyedy Mark J

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		A		7,490	A	$0(1)	21,040	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units granted on June 2, 2026. Price not applicable.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)